CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.

Paul J PockrosMichael FuchsBradley FreilichEugene SchiffAnita KohliEric J LawitzPaul A HellsternJanet Owens-GrilloCourtney Van BieneReshma ShringarpureLeigh MacConellDavid ShapiroDavid E Cohen

Published in: Liver international : official journal of the International Association for the Study of the Liver (2019)

The CONTROL study showed that OCA-induced increases in LDLc in patients with NASH were mitigated with atorvastatin. The combination of OCA and atorvastatin was generally safe and well tolerated (NCT02633956).

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
oxidative stress
diabetic rats
patient reported outcomes
endothelial cells
study protocol